Supplementary Materials

S1 – Search strategy for Ovid MEDLINE

Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) 1946 to September 09, 2020

#	Search Term	Search results
1	(group adj1 visit*).tw.	719
2	(group adj3 appointment*).tw.	232
3	(group medical adj2 visit*).tw.	83
4	(group medical adj2 clinic*).tw.	14
5	(group medical adj2 appointment*).tw.	28
6	(group medical adj2 care).tw.	11
7	(group medical adj2 meeting*).tw.	0
8	(group adj3 consultation*).tw.	724
9	(shared medical adj2 appointment*).tw.	159
10	(shared medical adj2 visit*).tw.	10
11	(cluster adj3 visit*).tw.	51
12	(group medical adj2 consultation*).tw.	5
13	(chronic care adj2 clinic*).tw.	42
14	exp Shared Medical Appointments/	24
15	(group clinic*).tw.	3085
16	/OR 1-15	5041
17	Limit 16 to yr= "2013-Current"	2500

Section on	Field	Notes	Codes
<u>Covidence</u>			
Identification	Country	See codes	1- Australia
			2- Canada
			3- China
			4- Netherlands
			5- United Kingdom
			6- United States
			7- Other
	Primary care setting	See codes	1- GP surgery
	(the default 'Setting'		2- Community health centre
	item on Covidence)		3- Other (specify as free text)
			4- Unclear
			888- Not reported
	Comments	Free text (if applicable	
	Setting (urban/rural)	Free text – e.g. in cit	v setting
Mothods	Design	Choose from dron-do	wn list ontions
methous	Aim of the study	Eroo toxt	
	Ain of the study	FIEE IEXI	
	Primary outcome	Free text - describe re	eported primary outcome
	Secondary outcome(s)	Free text - describe a	ny reported secondary
		outcome(s)	
	Statistical analysis	Free text - brief descr	iption of statistical analysis,
		including any details	on intention-to-treat and
		adjustment for cluster	ing (where appropriate). Note any
		problems/errors.	
	Timepoints reported	Free text - list all repo	orted, including baseline, in
	, ,	months since random	isation (for compliance with target
		behaviour)	
Population	Inclusion criteria	Free text	
	Exclusion criteria	Free text	
	Group differences	Free text	
	Clinical condition(s) for	See codes	1- Diabetes
	which SMA was held for		2- Osteoporosis only
			3- Chronic pain only
			4- Chronic neuromuscular
			disease only
			5- Multimorbidity
			6- Other (specify as free text)
	Description of	Free text	
	multimorbidity (where	1100 10/1	
	relevant)		
	Method(s) of	Free text	
	recruitment of patients		
	Number of clusters (if	Eree text only for cl	uster randomised controlled trials
	Subgroups mossured	Free text	
	and/or reported	Fiee lext	
	Total number	Free text	
	randomised (or total		
	population if cluster		
	randomised)		
	Were disadvantaged	See codes	0- No
	patient (groups)	-	1- Homelessness
	targeted/recruited?		2- Substance misuse

			3- Offending behavioural
			issues
			4- Mental ill-health
			5- Other (specify as free text)
		— , , , , , , , , , , , , , , , , , , ,	6- Unclear
	Withdrawals and	Free text (include det	alls on dropouts/non-attendance
	randomisation)	at sessions)	
	Baseline characteristics	Free text	
	– age (mean)		
	Baseline characteristics	Free text	
	– age (standard		
	deviation)		
	Baseline characteristics	Free text	
	– number of male		
	participants Receline cherecteristics	F	
	pumber of female	Free lext	
	narticinants		
	Baseline characteristics	Free text	
	– number of White		
	participants		
	Baseline characteristics	Free text	
	– number of non-White		
	participants Receive chorectoristics	Erec tout	
	– education (number)	Free lext	
	Baseline characteristics	Free text	
	– employment (number)		
Interventions	Intervention/control	Free text – name give	en by authors
	name		
	Number of participants	Free text	
	Number of elusters	Erectovt only relov	ant for eluctor randomized
	randomised to group	controlled trials (777	if NA)
	(CRCT only)		
	Authors' description of	Copy and paste all de	etails given by the authors about
	intervention (e.g., SMA,	the intervention. Plea	se include details from any of the
	GV, GC)	study papers.	
		Flag an maata link(a) t	
		where appropriate	o supplementary material(s),
	Description of co-	Free text	
	interventions (e.g., SMA		
	+ Peer 2 peer support)		
	Provider characteristics	Free text – e.g., male	; female; age; ethnicity
		In the section delivery of	f the SNAAe (including feeiliteters)
		involved in delivery o	r the SMAS (including facilitators)
		Involved in set-up/org	ganisation of the SMAs
		0 1 1 1 1	4 05
	Protessional	See codes – list all	1- GP 2 Other destar
	the SMAs including		
	facilitators)		4- Dietician/nutritionist
			5- Pharmacist
			6- Psychologist

		7- Physiotherapist
		8- Counsellor
		9- Social worker
		10- Other allied healthcare
		professional (specify as
		froe text)
		11 Other new healthcare
		11- Other non-nealthcare
		professional (specify as
		free text)
		12- Unclear
		888- Not reported
Professional	Free text	
background		
(organisation/set-up of		
the SMAs)		
Professional experience	Free text _ e.g. 15 ve	ars practicing purse. Masters
i iolessional experience	lovel psychology stud	ont registered distision for 8
	level psychology stud	ent, registered dietician for o
	years	
	Involved in delivery of	t the SMAs (including facilitators)
	Involved in set-up/org	anisation of the SMAs
Training in intervention	Free text - 2-hr trainin	g session: half day workshop:
facilitation	online training module	
	gg	
Training in intervention	Free text – e.a. Com	munication skills training: group
delivery	facilitation training	anitive behavioural skills training
Intervention relevant	Fron toxt or Com	potopoo Cortified boolth trainer
	Free lext – e.g., Com	petence Certilled health trainer,
competence	certificate în counselli	ng
O and in a firm of a man internet		
Continuity of providers	Free text – e.g., Sam	e provider; different providers for
who deliver the SMA	different topics; mix o	f same and different providers
sessions		
Mode of delivery	See codes	1- Face-to-face
		2- Teleconferencing
		3- Face-to-face and
		teleconferencing
		4- Other
		5- Unclear
		888- Not reported
Delivery channel	Free text – e.a. Pers	onal, self-help, mobile phone
	application (app) text	message (SMS) telephone
	email CD_ROM vide	oconferencing podcast
Delivery route	Soo oodoo	1 Audio
Delivery Ioule	See codes	1- AUUIO 2 Toxt
		3- PICTURE
		4- Experiential
		5- Unclear
		888- Not reported
Participants' materials	Free text – e.g., Leafl	et, booklet, book, webpage, app,
	device	
	(e.g., pedometer), cer	tificate, money, voucher
Providers' materials	Free text – e.a Sess	ion manual; pop-up reminders.
	self-monitoring sheets	S
Intervention materials	Free text - e.a. Fligib	ility forms questionnaires sign in
	forms	
Venue of SMA delivery	See codos	1 GB surgery
venue or Sivia delivery		r- OF Sulgely

Jastree text) 3. Mixed 4. Unclear 888- Not reported Duration of intervention (entre SMA programme) Free text Number of SMA sessions Free text Duration of SMA sessions Free text Duration of SMA sessions Free text Spacing of SMA sessions Free text Contact form See codes 1. Scheduled 2. Random 3. Proactive 4. Reactive 4. Reactive 5. Unclear 888- Not reported Intervention variation See codes 1. Scheduled 2. One size for all 3. Personalised 3. Personalised 4. Titrated 5. Adapted 6. Unclear 7. Other 888- Not reported 1. Titrated 5. Adapted 5. Adapted 6. Unclear 7. Other 888- Not reported 1. Titrated 5. Adapted 1. Unclear 7. Other 888- Not reported Tailoring source Free text - e.g. self-tailored, theory tailored, practitioner 5. Experimentation style Free text - e.g. asset, patient-centred, automated, semi-automated, personal. Delivery style Free text - e.g. listening, questioning, reflecting, pauses. Visual Style Free text - e.g. listening, questioning, reflecting, pauses.						2- Other	hired venue	(specify
Arman 3- MM80 4. Unclear 888- Not reported Buration of intervention (entire SMA programme) Free text Number of SMA sessions Free text Duration of SMA sessions Free text Spacing of SMA sessions Free text Contact form See codes 1- Scheduled 2. Random 3. Proactive 2. Random 3. Proactive Keactive 4. Reactive Sessions 5. Unclear B88- Not reported 1. None 2. One size for all 3. Personalised 4. Titrated 5. Adapted 6. Unclear B88- Not reported Tailoring source Free text - e.g. self-tailored, theory tailored, practitioner tailored, sem-automated, personal. Tailoring source Free text - e.g. asset-based, patient-centred, automated, sem-automated, personal. Delivery style Free text - e.g. asset-based, patient-centred, automated, sem-automated, personal. Delivery style Free text - e.g. asset-based, patient, centred, automated, sem-automated, personal. Communication style Free text - e.g. asset-based, patient, centred, automated, sem-automated, personal. Communication Free text - e.g. asset-based, patient, centred, automated, sem-automated, personal. Communication Free text - e.g. asset-based, patient, centred, automater, e.g. reading level, layout, depth of inf						as free	e text)	
Arm Prevention (entire SMA programme) Free text Number of SMA sessions Free text Duration of SMA sessions Free text Duration of SMA sessions Free text Spacing of SMA sessions Free text Contact form See codes 1 - Scheduled 2. Random 3. Proactive 4. Reactive 5. Unclear Contact form See codes 1 - Scheduled 2. Random 3. Proactive 4. Reactive 5. Unclear Intervention variation See codes 1 - Scheduled 2. Random 3. Proactive 4. Reactive 5. Unclear Intervention variation See codes 1 - None 2. One size for all 3. Personalised 4. Titrated 5. Adapted 6. Unclear 7. Other 888. Not reported Tailoring source Free text - e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text - e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text - e.g. asset, patient-centred, automated, semi-automated, personal. Delivery style Free text - e.g. asset, patient-centred, automated, semi-automated, personal. Delivery style Free text - e.g. altenning, questioning, reflecting, feacting Communication style Free text - e.g. patient led, practitioner led, narrative. Commun						3- Mixed		
Duration of intervention (entire SMA programme) Free text Number of SMA sessions Free text Duration of SMA sessions Free text Duration of SMA sessions Free text Spacing of SMA sessions Free text Spacing of SMA sessions Free text Contact form See codes 1 - Scheduled Andom 3 - Proactive - Reactive - Unclear - Unclear 888 - Not reported - None 1 - None - One size for all 3 - Presonalised - Tailoring source Free text - e.g. self-tailored, theory tailored, practitioner tailored Tailoring source Free text - e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text - e.g. apatient led, practitioner led, narrative. Communication style Free text - e.g. patient led, practitioner led, narrative. Communication free text - e.g. coding level, layout, depth of information. - No Theoretical See codes 0 - No Underpinnings - Free text - e.g. coding level, layout, depth of information. - Yes (specify as free text) Costs reported/funding secured Free text						4- Unclea	ar 	
Duration of SMA programme) Free text Number of SMA sessions Free text Duration of SMA sessions Free text Spacing of SMA sessions Free text Spacing of SMA sessions Free text Contact form See codes 1 - Scheduled Intervention variation See codes 1 - Scheduled Intervention variation See codes 1 - None Intervention variation Free text - e.g. salet-tailored, theory tailored, practitioner Intervention variation Free text - e.g. saset-based, patient-contred, automated, semi-automated, personal. Delivery style Free text - e.g. listening, questioning, reflecting, pauses. Visual style Free text - e.g. listening, colour scheme. Communication style Free text - e.g. listening, colour scheme.						888- Not	reported	
Number of SMA sessions Free text Duration of SMA sessions Free text Frequency of SMA sessions Free text Contact form See codes 1 - Scheduled Contact form See codes 1 - Scheduled Intervention variation See codes 1 - Scheduled Intervention variation See codes 1 - None 2 - One size for all 3 - Proactive 4 - Titrated 5 - Adapted 6 - Unclear 6 - Unclear 888 - Not reported 1 - Schapted Tailoring source Free text - e.g. self-tailored, theory tailored, practitioner tailored. Standardisation Free text - e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text - e.g. patient led, practitioner led, narrative. Communication style Free text - e.g. patient led, practitioner led, narrative. Communication style Free text - e.g. patient led, practitioner scheme. Complexity Free text - e.g. patient led, practitioner scheme. Complexity Free text - e.g. branding, colour scheme. Complexity Free text - e.g. reading level, layout, depth of informa		Duration of in (entire SMA programme)	ntervention	Free text				
Duration of SMA sessions Free text Frequency of SMA sessions Free text Spacing of SMA sessions Free text Contact form See codes 1 - Scheduled Contact form See codes 1 - Scheduled Intervention variation See codes 1 - None Intervention variation Free text - e.g. self-tailored, theory tailored, practitioner Tailoring source Free text - e.g. self-tailored, theory tailored, practitioner Standardisation Free text - e.g. patient led, practitioner led, narrative. Communication style Free text - e.g. patient led, practitioner led, narrative. Communication Free text - e.g. listening, questioning, reflecting, pauses. Visual style Free text - e.g. logo, branding, colour scheme. Complexity Free text - e.g. reading level, layout, depth of information. Theoretical underpinnings <t< th=""><th></th><th>Number of S sessions</th><th>MA</th><th>Free text</th><th></th><th></th><th></th><th></th></t<>		Number of S sessions	MA	Free text				
Frequency of SMA sessions Free text Spacing of SMA sessions Free text Contact form See codes 1. Scheduled 2. Random 3. Proactive 4. Reactive 5. Unclear 888- Not reported Intervention variation See codes 1. None 2. One size for all 3. Personalised 4. Titrated 5. Adapted 6. Unclear 7. Other 888- Not reported Tailoring source Free text – e.g. self-tailored, theory tailored, practitioner tailored, theory tailored, practitioner tailored, semi-automated, personal. Tailoring source Free text – e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text – e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text – e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text – e.g. asset-based, patient-centred, automated, semi-automated, personal. Communication style Free text – e.g. an intervention, guestioning, reflecting, pauses. Visual style Free text – e.g. listening, questioning, reflecting, pauses. Visual style Free text – e.g. coding level, layout, depth of information. Theoretical underpinnings See codes 0. No 1. Yes (specify as free text) 2. Unclear Costs reported/funding secured Free text -e.g. reading level, layout, depth of information. Thealthcare finance context- health insurance/free at point of use		Duration of S sessions	SMA	Free text				
Spacing of SMA sessions Free text Contact form See codes 1 - Scheduled 2 - Random 3 - Proactive 4 - Reactive 5 - Unclear 888 - Not reported Intervention variation See codes 1 - None 2 - One size for all 3 - Personalised 4 - Titrated 5 - Adapted 6 - Unclear 7 - Other 888 - Not reported Tailoring source Free text - e.g. self-tailored, theory tailored, practitioner tailored. Standardisation Free text - e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text - e.g. asset-based, patient-centred, authoritarian. Communication style Free text - e.g. patient led, practitioner led, narrative. Communication style Free text - e.g. listening, questioning, reflecting, pauses. Visual style Free text - e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0 - No Costs reported/funding secured Free text - e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0 - No Costs reported/funding secured Free text - Yes (specify as free text) 2 - Unclear Costs reported/funding secured Free text - Yes (specify as free text) 2 - Unclear Costs reported/funding secured Free text - Ne		Frequency or sessions	f SMA	Free text				
Contact form See codes 1 - Scheduled 2 - Random 3 - Proactive 4 - Reactive 5 - Unclear 888- Not reported 1 - None Intervention variation See codes 1 - None 2 - One size for all 3 - Personalised 4 - Titrated 5 - Adapted 6 - Unclear 888- Not reported 7 - Other 886 - Not reported 1 - Scenarization Free text – e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text – e.g. patient led, practitioner led, narrative. Communication style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. reading level, layout, depth of<		Spacing of S sessions	MA	Free text				
4. Reactive 4. Reactive 5. Unclear 888- Not reported Intervention variation See codes 1- None 2. One size for all 3. Personalised 4. Titrated 5. Adapted 6. Unclear 7. Other 888- Not reported Tailoring source Free text - e.g. self-tailored, theory tailored, practitioner tailored. Standardisation Free text - e.g. an intervention manual is followed, automated, personal. Delivery style Free text - e.g. asset-based, patient-centred, automated, personal. Communication style Free text - e.g. asset-based, patient-centred, arrative. Communication style Free text - e.g. listening, questioning, reflecting, techniques pauses. Visual style Visual style Free text - e.g. leading level, layout, depth of information. Theoretical underpinnings See codes 0- No 1- Yes (specify as free text) 2- Unclear Costs reported/funding secured Free text - g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No		Contact form		See code	S	1- Schedu 2- Randor 3- Proactiv	iled n ve	
Intervention variation See codes 1 - None Intervention variation See codes 1 - None 2 - One size for all 3 - Personalised 4 - Titrated 5 - Adapted 6 - Unclear 7 - Other 888- Not reported 888-Not reported Tailoring source Tailoring source Free text – e.g. self-tailored, theory tailored, practitioner tailored. Standardisation Standardisation Free text – e.g. an intervention manual is followed, automated, personal. Delivery style Free text – e.g. asset-based, patient-centred, automated, semi-automated, personal. Delivery style Free text – e.g. listening, questioning, reflecting, pauses. Visual style Free text – e.g. logo, branding, colour scheme. Computication Free text – e.g. logo, branding, colour scheme. Computication Free text – e.g. logo, branding, colour scheme. Visual style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. logo, branding, colour scheme. Costs reported/funding secured See codes 0 - No underpinnings Free text - g. logo, branding, colour scheme. Costs reported/funding secured Free text - Yes (specify as free text)						4- Reactiv 5- Unclear	e	
Intervention variation See codes 1 - None 2 - One size for all 3 - Personalised 4 - Titrated 5 - Adapted 6 - Unclear 7 - Other 888 - Not reported 888 - Not reported Tailoring source Free text - e.g. self-tailored, theory tailored, practitioner Standardisation Free text - e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text - e.g. asset-based, patient-centred, automated, semi-automated, personal. Delivery style Free text - e.g. listening, questioning, reflecting, pauses. Visual style Free text - e.g. logo, branding, colour scheme. Communication Free text - e.g. logo, branding, colour scheme. Complexity Free text - e.g. logo, branding, colour scheme. Visual style Free text - e.g. logo, branding, colour scheme. Complexity Free text - e.g. logo, branding, colour scheme. Complexity Free text - e.g. logo, branding, colour scheme. Costs reported/funding secured See codes 0 - No 1 - Yes (specify as free text) 2 - Unclear Costs reported/funding secured Free text - See text Healthcare finance context - health insurance/free at point of use Free text - See intervention Mean Standard Sample						888- Not r	eported	
Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline 0- No Presonalised 4 - Titrated 5 - Adapted 6 - Unclear 7 - Other 888- Not reported Tailoring source Free text - e.g. self-tailored, theory tailored, practitioner tailored. Standardisation Free text - e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text - e.g. asset-based, patient-centred, automaterian. Communication style Free text - e.g. patient led, practitioner led, narrative. Communication techniques Free text - e.g. listening, questioning, reflecting, pauses. Visual style Free text - e.g. logo, branding, colour scheme. Complexity Free text - e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No 1- Yes (specify as free text) 2- Unclear Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample deviation Sample		Intervention	ariation	See code	S	1-None	<i>c</i>	
Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline 0- No Trailor of use Free text 0- No 1- Yes (specify as free text) 2- Unclear						2- One siz	tor all	
Visual style Free text - e.g. self-tailored, theory tailored, practitioner tailored. Communication style Free text - e.g. asset-based, patient-centred, automated, personal. Delivery style Free text - e.g. asset-based, patient-centred, automated, personal. Delivery style Free text - e.g. asset-based, patient-centred, automated, personal. Communication style Free text - e.g. asset-based, patient-centred, automated, personal. Visual style Free text - e.g. listening, questioning, reflecting, techniques Visual style Free text - e.g. logo, branding, colour scheme. Complexity Free text - e.g. ceading level, layout, depth of information. Theoretical underpinnings See codes 0- No 1- Yes (specify as free text) 2- Unclear Costs reported/funding secured Free text - Standard Healthcare finance context- health insurance/free at point of use Free text - Standard Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Sample deviation Intervention intervention isize Intervention Size						3- Person	alised	
 G - Unclear F - Other 888- Not reported Tailoring source Free text – e.g. self-tailored, theory tailored, practitioner tailored. Standardisation Free text – e.g. an intervention manual is followed, automated, personal. Delivery style Free text – e.g. asset-based, patient-centred, autonitarian. Communication style Free text – e.g. patient led, practitioner led, narrative. Communication techniques pauses. Visual style Free text – e.g. listening, questioning, reflecting, pauses. Visual style Free text – e.g. logo, branding, colour scheme. Complexity Theoretical underpinnings Costs reported/funding secured secured Healthcare finance context- health insurance/free at point of use Outcomes (e.g. HbA1C)						5- Adapte	n Vd	
Visual style Free text - e.g. self-tailored, theory tailored, practitioner tailored. Communication style Free text - e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text - e.g. asset-based, patient-centred, authoritarian. Communication style Free text - e.g. patient led, practitioner led, narrative. Communication style Free text - e.g. patient led, practitioner led, narrative. Communication style Free text - e.g. patient led, practitioner led, narrative. Communication style Free text - e.g. listening, questioning, reflecting, pauses. Visual style Free text - e.g. logo, branding, colour scheme. Complexity Free text - e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No Costs reported/funding secured Free text Visual style Healthcare finance context- health insurance/free at point of use Free text Visual style Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Sample Intervention Intervention Intervention Intervention Intervention						6- Unclea	ur in the second s	
Tailoring source Free text – e.g. self-tailored, theory tailored, practitioner tailored. Standardisation Free text – e.g. an intervention manual is followed, automated, personal. Delivery style Free text – e.g. asset-based, patient-centred, authoritarian. Communication style Free text – e.g. patient led, practitioner led, narrative. Communication style Free text – e.g. listening, questioning, reflecting, pauses. Visual style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No Costs reported/funding secured Free text See codes 1- Yes (specify as free text) 2- Unclear Costs reported/funding secured Free text Free text - e.g. reading level, layout, depth of information. Mean Standard Sample deviation See codes 0- No 1 Yes (specify as free text) 2- Unclear 2- Unclear See context- health insurance/free at point of use Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Intervention Intervention size Ideviation size						7- Other		
Tailoring source Free text – e.g. self-tailored, theory tailored, practitioner tailored. Standardisation Free text – e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text – e.g. asset-based, patient-centred, authoritarian. Communication style Free text – e.g. patient led, practitioner led, narrative. Communication techniques pauses. Visual style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No Costs reported/funding secured Free text -e.g. reading level, layout, depth of information. Healthcare finance context- health insurance/free at point of use Free text -e.g. reading level, layout, depth of information. Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Sample Intervention Intervention Intervention Size Intervention Size						888- Not r	eported	
Standardisation Free text – e.g. an intervention manual is followed, automated, semi-automated, personal. Delivery style Free text – e.g. asset-based, patient-centred, authoritarian. Communication style Free text – e.g. patient led, practitioner led, narrative. Communication techniques Free text – e.g. listening, questioning, reflecting, pauses. Visual style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No 1- Yes (specify as free text) 2- Unclear Costs reported/funding secured Free text - Healthcare finance context- health insurance/free at point of use Free text Post-intervention Qutcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Sample Intervention Intervention Intervention ize Intervention Intervention		Tailoring sou	rce	Free text tailored.	– e.g. self-ta	ailored, theo	ory tailored,	practitioner
Delivery style Free text – e.g. asset-based, patient-centred, authoritarian. Communication style Free text – e.g. patient led, practitioner led, narrative. Communication style Free text – e.g. listening, questioning, reflecting, pauses. Visual style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No Costs reported/funding secured Free text - e.g. reading level, layout, depth of information. Lealthcare finance context- health insurance/free at point of use Free text 0- No Mean Standard Sample Mean Mean Standard Sample deviation Intervention Intervention Intervention Intervention		Standardisation		Free text automate	– e.g. an inf d, semi-auto	tervention m omated, per	nanual is foll sonal.	owed,
Communication style Free text – e.g. patient led, practitioner led, narrative. Communication techniques Free text – e.g. listening, questioning, reflecting, pauses. Visual style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No Costs reported/funding secured Free text - Yes (specify as free text) 2- Unclear Costs reported/funding secured Free text Healthcare finance context- health insurance/free at point of use Free text Pre-intervention/baseline Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Sample Intervention Intervention Intervention Intervention Intervention Size		Delivery style	9	Free text authoritar	– e.g. asset ian.	-based, pat	ient-centred	3
Communication techniques Free text – e.g. listening, questioning, reflecting, pauses. Visual style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No Costs reported/funding secured Free text - Healthcare finance context- health insurance/free at point of use Free text - Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Intervention Intervention size Intervention size		Communicat	ion style	Free text	– e.g. patiei	nt led, pract	itioner led, n	arrative.
techniques pauses. Visual style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No Image: Costs reported/funding secured Free text 2- Unclear Kealthcare finance context- health insurance/free at point of use Free text Free text Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention/ angle deviation Mean Standard Sample Mean Standard Intervention Intervention Intervention Intervention		Communicat	ion	Free text	– e.g. listen	ing, questio	ning, reflecti	ing,
Visual style Free text – e.g. logo, branding, colour scheme. Complexity Free text – e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No Image: Costs reported/funding secured See codes 0- No Healthcare finance context- health insurance/free at point of use Free text Image: Costs-intervention/baseline Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention/baseline Mean Standard Sample Mean Standard Intervention Intervention Image: Control Image: Control Image: Control		techniques		pauses.			<u> </u>	
Complexity Free text – e.g. reading level, layout, depth of information. Theoretical underpinnings See codes 0- No 1- Yes (specify as free text) 2- Unclear Costs reported/funding secured Free text Healthcare finance context- health insurance/free at point of use Free text Outcomes (e.g. HbA1C) Arm Mean Standard deviation Mean Standard deviation Size Mean Standard deviation Sample Intervention Intervention Control Intervention		Visual style		Free text – e.g. logo, branding, colour scheme.				
Theoretical underpinnings See codes 0- No underpinnings 1- Yes (specify as free text) Costs reported/funding secured Free text Healthcare finance context- health insurance/free at point of use Free text Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention/size Mean Standard deviation Sample deviation Standard deviation Sample deviation Intervention Intervention Intervention Intervention Intervention Intervention		Complexity		informatio	– e.g. readi on.	ng level, lay	out, depth o	T
under prinnings 1- Yes (specify as free text) 2- Unclear Costs reported/funding secured Free text Healthcare finance context- health insurance/free at point of use Free text Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Sample Intervention Intervention Intervention Intervention Intervention Intervention		Ineoretical		See code	S	0- No	nooifi a - f	a taxt
Costs reported/funding secured Free text Healthcare finance context- health insurance/free at point of use Free text Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard deviation Sample deviation Standard deviation Sample deviation Intervention Intervention Intervention Intervention Intervention Intervention		unaerpinning	S			1-Yes (s	pecity as tre	e text)
Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Sample Intervention Intervention Intervention Intervention Intervention		Costs reporte	d/fundina	Free text				
Healthcare finance context- health insurance/free at point of use Free text Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Sample Intervention Intervention Intervention Intervention Intervention Intervention		secured	Jananang					
Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard Sample Mean Standard Sample Intervention Intervention Intervention Intervention Intervention		Healthcare fi	nance th	Free text				
Outcomes (e.g. HbA1C) Arm Pre-intervention/baseline Post-intervention Mean Standard deviation Sample size Mean Standard deviation Sample size Intervention Intervention Intervention Intervention Intervention		insurance/fre	e at point					
Outcomes (e.g. HbA1C)ArmPre-intervention/baselinePost-interventionMeanStandardSample deviationMeanStandard deviationSample sizeInterventionControlInterventionIntervention		5. 200						
(e.g. HbA1C)MeanStandard deviationSample sizeMeanStandard deviationSample sizeInterventionControlInterventionInterventionIntervention	Outcomes	Arm	Pre-int	ervention/ba	aseline	P	ost-intervent	ion
Intervention Control	(e.g. HbA1C)		Mean	Standard deviation	Sample size	Mean	Standard deviation	Sample size
		Intervention Control						

888 = Not reported; 777 = Not applicable; 999 = Missing data

Trial No.	Author & date	Paper title
1	Baqir 2020	Osteoporosis group consultations are as effective as usual care: Results from a non-inferiority randomized trial
2	Berry 2016	Imbedding Interdisciplinary Diabetes Group Visits Into a Community-Based Medical Setting
3	Clancy 2003a	Evaluating group visits in an uninsured or inadequately insured patient population with uncontrolled diabetes
3	Clancy 2003b	Evaluating Concordance to American Diabetes Association Standards of Care for Type 2 Diabetes Through Group Visits in an Uninsured or Inadequately Insured Patient Population
4	Clancy 2007a	Group Visits: Promoting Adherence to Diabetes Guidelines
4	Clancy 2007b	Further Evaluating the Acceptability of Group Visits in an Uninsured or Inadequately Insured Patient Population With Uncontrolled Type 2 Diabetes
4	Clancy 2008	Do Diabetes Group Visits Lead to Lower Medical Care Charges?
5	Cohen 2011	Pharmacist-Led Shared Medical Appointments for Multiple Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
6	Cole 2013	Effectiveness of Prediabetes Nutrition Shared Medical Appointments
7	Coleman 2001	Reducing Emergency Visits in Older Adults with Chronic Illness. A Randomized, Controlled Trial of Group Visits
7	Scott 2004	Effectiveness of a Group Outpatient Visit Model for Chronically III Older Health Maintenance Organization Members: A 2-Year Randomized Trial of the Cooperative Health Care Clinic
8	Crowley (2013)	Impact of Baseline Insulin Regimen on Glycemic Response to a Group Medical Clinic Intervention
8	Crowley (2014)	Can Group Medical Clinics Improve Lipid Management in Diabetes?
8	Edelman (2010)	Medical Clinics Versus Usual Care for Patients With Both Diabetes and Hypertension: a randomised trial
8	Eisenberg (2019)	Effect of a group medical clinic for veterans with diabetes on body mass index
9	Crowley (2017)	Jump starting shared medical appointments for diabetes with weight management: Rationale and design of a randomized controlled trial
9	Yancy (2020)	Comparison of Group Medical Visits Combined With Intensive Weight Management vs Group Medical Visits Alone for Glycemia in Patients With Type 2 Diabetes A Noninferiority Randomized Clinical Trial
10	Drake 2018	Integration of Personalized Health Planning and Shared Medical Appointments for Patients with Type 2 Diabetes Mellitus
11	Ee (2020)	Shared Medical Appointments and Mindfulness for Type 2 Diabetes—A Mixed- Methods Feasibility Study
12	Gao (2015)	Evaluation of Group Visits for Chinese Hypertensives Based on Primary Health Care Center
13	Gardiner (2017)	Design of the integrative medical group visits randomized control trial for underserved patients with chronic pain and depression
13	Gardiner (2019)	Effectiveness of integrative medicine group visits in chronic pain and depressive symptoms: A randomized controlled trial
14	Liu (2013)	Effectiveness of using group visit model to support diabetes patient self- management in rural communities of Shanghai: a randomized controlled trial
15	Naik (20 <u>11)</u>	Comparative Effectiveness of Goal Setting in Diabetes Mellitus Group Clinics: randomized clinical trial
16	Schilinger (2008)	Seeing in 3-D: Examining the Reach of Diabetes Self-Management Support Strategies in a Public Health Care System
16	Schilinger (2009)	Effects of Self-Management Support on Structure, Process, and Outcomes Among Vulnerable Patients With Diabetes

S3 – List of included peer-reviewed papers

16	Wallace	Influence of Patient Characteristics on Assessment of Diabetes Self-
	(2013)	Management Support
17	Simon	Quality improvement in chronic care delivery for patients with arterial
	(2015)	hypertension through Group Medical Visits: Patient acceptance and
	(2013)	attendance in the German pilot project
18	Taveira	Pharmacist-Led Group Medical Appointments for the Management of Type 2
	(2011)	Diabetes with Comorbid Depression in Older Adults
19	Taveira	Interventions to Maintain Cardiac Risk Control After Discharge from a
	(2014)	Cardiovascular Risk Reduction Clinic: A Randomized Controlled Trial
20	Vaughan	Integrating CHWs as Part of the Team Leading Diabetes Group Visits A
	(2017)	Randomized Controlled Feasibility Study
21	Vaughan	A Telehealth-supported, Integrated care with CHWs, and MEdication-access
	(2020)	(TIME) Program for Diabetes Improves HbA1c: a Randomized Clinical Trial
22	Wagner	Chronic Care Clinics for Diabetes in Primary Care: a system side randomized
	(2001)	trial
23	14/11 (2019)	Costs and effectiveness of pharmacist-led group medical visits for type-2
	vvu (2018)	diabetes: A multi-center randomized controlled trial

S4 – Outcomes reported by studies

Most trials (n=19, 83%) included at least one biomedical health indicator, particularly trials of SMAs for a single health condition (see Table S4). The most common measure (n=18, 78%), was HbA1C (%) [23,25,26,29–31,33,34,37–44,46,53]. Three of these trials were of SMAs for patients with multiple LTCs – diabetes with CVD risk or diabetes and overweight [44]. Two trials reported the proportion of patients meeting HbA1C goals at 6 months [40,43].

Other biomedical health indicators included systolic and or diastolic blood pressure (DBP) reported in 14 trials [23,26–30,37,38,40,42–49,53]. LDL cholesterol (mg/dL) was measured in 12 trials [23–30,37,38,40,42–49,53]. HDL cholesterol mg/dL was measured in 8 trials [23–29,37,38,41,44–49]. Triglycerides, mg/dL, were measured in 8 trials [23–29,31,37,38,44–49]. BMI, (kg/m²), was measured in six trials[30,31,34,37,38,50]. Change in BMI was reported at 12 months in 2 trials [29,32]. Mean weight loss (Kg) was measured in three trials [31,38,44], percentage of group to achieve weight loss goals (\geq 5% weight loss/any weight loss/any weight gain) was measured in one trial [37] and change in weight from baseline was reported in another trial [29].

Several trial outcome measures included psychological and well-being measures. Participant self-completion questionnaires were used to measure depression in seven trials [21,22,31,32,39,43,46–50], quality of life in six trials [19–22,31,34–36,42,53], and diabetes self-efficacy in seven trials [19,23,30,33–36,46–50].

There was much heterogeneity in the outcomes reported by studies and measures used to measures these outcomes. See Table A5. Behavioural outcomes included measures of physical activity in six trials [23,31,34,40,44,50], healthcare service use was measured in nine trials [19,22,23,25,29,39,41,43,46] and medication adherence in four trials [40,46,50,52].

Health service costs were measured in seven trials reported as cost per study arm [19,39,52] cost per patient per year [25,26,46], per person [42].

Trial (condition)	Outcomes (scales/measures)
	Biomedical: NR
	Psychological: patient satisfaction with group clinics
Baqir 2020 (Osteoporosis)	Behavioural: MPR (mean possession ratio) with bisphosphonates (MPR is a useful surrogate marker for adherence), persistence with treatment with bisphosphonates in months after treatment was initiated (calculated as the number of months treatment taken before stopping)
	Costs: cost differences between the group and 1:1 clinics.
	Biomedical: Blood pressure (systolic and diastolic), A1C %, fasting lipid panel (triglycerides, LDL, HDL), glucose testing, diet, medical care, heart rate (beat/min).
Berry 2016	Psychological: Stanford Diabetes Self-Management Questionnaire (general health, symptoms (fatigue, fear, worry, shortness of breath, pain etc.)
(Diabetes)	Behavioural: Physical activities during the past week, confidence about doing things, daily activities, health care service use
	Costs: NR
	Other: NR
	Biomedical : HbA1c (%), cholesterol (mg/dl), triglycerides (mg/dl), HDL (mg/dl), LDL (mg/dl), Primary Care Assessment Tool [PCAT],
	Psychological: Trust in Physician Scale
	Behaviours: SMA attendance
(Diabetes)	Cost: charges (outpatient, inpatient, and emergency room costs and use)
(Elaboroo)	Other: mean total criteria met for 10 process-of-care indicators (up-to-date HbA1c levels and lipid profiles; urine for microalbumin; use of ACE inhibitor or angiotensin receptor blocker, especially in the face of microalbuminuria; use of lipid-lowering agents for LDL levels <100 mg/dl; daily use of aspirin; annual foot examinations; annual referrals for retinal examinations; and immunizations against streptococcal pneumonia and influenza)
	Biomedical: HbA1c (%), lipid profiles (total cholesterol, HDL, LDL, triglycerides), blood pressure,
Clancy 2007a,b,2008	Psychological: Diabetes Locus of Control Survey, trust in the healthcare, provider perception of characteristics
(Diabetes)	Behaviour: patients' attendance to group visits
(Diabotos)	Costs : charges (portioned into outpatient visits, emergency department visits, and inpatient stays)
	Other: Primary Care Assessment Tool [PCAT]
Cohen 2011	Biomedical : Proportion of patients achieving target goals as recommended by the ADA (A1C, LDL, systolic blood pressure, weight),
(Diabetes CVD risk)	Psychological: Quality-of-life questionnaire (VR-36), Perceived Competence
	Behavioural : medication adherence (individual medications/any cholesterol medication/total antihypertensive medications/total diabetes medications/total

Table S4: All outcomes (and measures) reported by trials

	cholesterol medications), self care activities (general diet, specific diet, exercise, blood sugar testing, foot care, number of cigarettes smoked per day),
	Other: NR
	Biomedical : Weight, BMI, systolic blood pressure, diastolic blood pressure, HbA1C (%), fasting blood glucose (mg/dl), total cholesterol, LDL, HDL, triglycerides) albumin-creatinine ratio
Cole 2013	Psychological: NR
(Prediabetes)	Behavioural: NR
	Costs: NR
	Other: NR
	Biomedical: NR
*Coleman 2001	Psychological: NR
(Chronic conditions)	Behavioural: Percentage of participants who made one or more emergency visits, the average number of emergency visits, repeated emergency department visits, hospitalisations, primary care visits, primary care + group visits, number of group visits attended [intervention participants only]
	Costs: NR
	Other: NR
	Biomedical: NR
*Scott 2004 (Chronic conditions)	Psychological and wellbeing : quality of life, <i>self-efficacy scale (confidence communicating with my physician, confidence managing my disease, confidence doing chores, confidence with social activities, confidence managing depression),</i> patient satisfaction (with PCP, PCP attentiveness, PCP unhurriedness, PCP explanation of condition, time spent with PCP, clinic nurse, overall quality of care, amount of health education), patient satisfaction at 24 months with (talking to PCP about advanced directives, talking with the pharmacist, education with the pharmacist, education from the nurse), functional outcomes (health status and advanced, household, and basic Activities of Daily Living),
	Behavioural : Healthcare utilisation (clinic vists/patient; pharmacy fills/patient; hospital admissions/patient; hospital observation admissions/patient; hospital outpatient visits/patient; professional services/patient; emergency visits/patient; skilled nursing facility admissions/patient; home visits/patient), patients' attendance to group visits
	Costs : costs of healthcare utilisation (clinic, pharmacy, hospital, hospital observation, hospital outpatient, professional services, emergency room, skilled nursing facility, home health, cost of termination from Kaiser Permanente, total cost)
	Biomedical : HbA1c, BMI, blood pressure (systolic and diastolic), and low-density lipoprotein
Drake 2018 (Diabetes)	Psychological : Diabetes Empowerment Scale-Short Form (diabetes-specific health self-management skills), General Self-Rated Health (GSRH), PHQ-2 (depression screening tool), visual goal progress scale, patient satisfaction, the 13-item Patient Activation Measure (self-management and patient engagement)
	Behavioural: retention
	Costs: NR
	Other: NR

**Edelman (2010) (Diabetes and hypertension)	 Biomedical: HbA1c, Diastolic BP, Systolic BP, mean adverse events (hypoglycaemic episodes-falls or light-headedness), Behavioural: medication adherence, blood pressure control, HbA1C control, Hospital admissions, ED visits (primary care and emergency care visits by using Veterans Affairs–specific codes. Visit counts are exclusive of group clinic sessions), attendance rates Psychological: perceived competence score: Self-efficacy, Costs: cost of SMAs Costs: NR
	Biomedical : HbA1c (change in HbA1c from study baseline to study end), rates of hypoglycaemia or a self-reported episode of hypoglycaemia Psychological: Self-efficacy(measured by the Perceived Competence Scale (PCS))
	B the investorie of the formation of the
	Benavioural: attendance rates
	Costs: NR
**Crowley (2013)	Other: NR
(Diabetes and hypertension)	
	Biomedical : Mean total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglyceride levels as continuous outcomes, generated a dichotomous outcome variable indicating whether patients met Adult Treatment Panel III criteria for LDL-C control (LDL-C 400 mg/dL, LDL-C was not reported.
**Crowley (2014)	Psychological: NR
(Diabetes and hypertension)	Behavioural : medication use (intensification of LDL-C-lowering medications during the study period)
	Costs: NR
	Other: NR

	Biomedical: HbA1c (also time in range/mean blood glucose); Anthropometric measures (weight, BMI, and hip circumference, and waist/hip circumference ratio), Blood pressure (systolic and diastolic), Total cholesterol, Triglycerides. Glycemic management, Fasting lipids		
Ee 2020	Psychological: depression (Becks depression inventory), Quality of Life (EQ5D5L sub groups: anxiety, mobility, pain discomfort, self-care, usual activity, Visual acuity scale), Anxiety (State Anxiety Index) Diabetes-related distress, Patient-Reported Outcomes Information System questionnaire (PROMIS-29)		
(Diabetes)	Behavioural: Self-reported diet quality (daily serves of vegetables and fruit, weekly serves of takeaways) from the Population Health Survey Questionnaire, Physical activity levels, Number of minutes of mindfulness practice per week, Number of minutes of mindfulness practice per week, Recruitment rates, Retention rate		
	Costs: NR		
	Other: Patient-Reported Outcomes Information System questionnaire (PROMIS-29) (Pain intensity, anxiety, depression, fatigue, pain interference, physical function, sleep, social),		
	Biomedical: Systolic BP, Diastolic BP, BMI,		
	Psychological and wellbeing: Self-reported health, energy, Self-efficacy of managing symptoms/disease/ physical activity, attitudes, depression, health distress		
Gao 2015 (Hypertension)	Behavioural: treatment compliance (never taking medicine, taking without compliance, taking with compliance), physical activities, dietary adjusting (NA, never adjusting; AWOC, adjusting without compliance; AWC, adjusting with compliance.)		
	Costs: NR		
	Other: patient-physician communication, social support, coping skills, beliefs		
	Biomedical : Brief Pain Inventory (Assesses pain severity and interference, average pain score in last 7 days), Pain,		
Gardiner 2019 (Chronic pain and	Psychological and wellbeing : Patient Health Questionnaire (PHQ-9) a self-reported depression scale, Pain Self Efficacy Questionnaire (PSEQ) Patient Activation Measure, Short Form 12 Health Survey QoL, Common opioid misuse measure, Perceived Stress Scale.		
depression)	Behavioural: Self- Reported Pain Medication Use (past 7 days), ED use		
	Costs: NR		
	Other: NR		
	Other: NR Biomedical: BMI, systolic BP, diastolic BP		
Liu (2013)	Other: NR Biomedical: BMI, systolic BP, diastolic BP Psychological and wellbeing: Self-management behaviour scores (diet, aerobic exercise, practice of cognitive symptom management, communication with doctor, examining feet), Diabetes Self-Efficacy Scale, health status (self-rated health, energy, health distress, fatigue, illness intrusiveness, depression)		
Liu (2013) (Diabetes)	Other: NR Biomedical: BMI, systolic BP, diastolic BP Psychological and wellbeing: Self-management behaviour scores (diet, aerobic exercise, practice of cognitive symptom management, communication with doctor, examining feet), Diabetes Self-Efficacy Scale, health status (self-rated health, energy, health distress, fatigue, illness intrusiveness, depression) Behavioural: NR		
Liu (2013) (Diabetes)	Other: NR Biomedical: BMI, systolic BP, diastolic BP Psychological and wellbeing: Self-management behaviour scores (diet, aerobic exercise, practice of cognitive symptom management, communication with doctor, examining feet), Diabetes Self-Efficacy Scale, health status (self-rated health, energy, health distress, fatigue, illness intrusiveness, depression) Behavioural: NR Costs: NR		

	Biomedical: HbA1C (%), [BMI and systolic BP only measured at baseline]
	Psychological: Diabetes Self-Efficacy
Naik (2011) (Diabetes)	Behavioural: NR
	Costs: NR
	Other: NR
	Biomedical: HbA1C (%), BMI, blood pressure, BMI
*** Schilinger (2008/09) (Diabetes)	Psychological and wellbeing : Diabetes Quality Improvement Programe Diabetes Self-Efficacy, weekly self-care, quality of life (Short Form-12) functional status (restricted activity; bed days, prior month),
	Costs : NR Behavioural : exercise (estimated minutes of moderate and vigorous physical activity on each of the days)
	Other : reach (participant among clinics, clinicians, and patients; patient representativeness; patient engagement with SMA), structure of care, Patient Assessment of Chronic Illness Care, patient reports of providers' communication over the prior year (Interpersonal Processes of Care for Diverse Populations),
	Biomedical : HbA1C, Systolic BP, Diastolic BP, BMI, Behavioural and Functional outcomes (spent most of the day in bed due to health problems" and the extent to which diabetes prevented them from carrying out normal daily activities (diabetes interference),
	Psychological wellbeing: _quality of life (Short Form (SF)-12 instrument), Test of Functional Health Literacy in Adults (0-36), Social support network, Health Status
***Wallace 2013	Behavioural : self-management behaviours (eating healthy foods, following a diabetic diet, exercising, self-monitoring of blood glucose, and caring for one's feet)
(Diabetes)	Other: PACIC rating . (The PACIC is a questionnaire consisting of 26 items with responses ranging from almost never (0) to almost always (5), includes: Delivery System Design/ Decision Support (e.g., Given a written list of things I should do to improve my health), Goal Setting (e.g., Asked to talk about my goals in caring for my illness), Problem-Solving/ Contextual Counseling (e.g., Helped make a treatment plan that I could do in my daily life), and Follow-Up/Coordination (e.g., Contacted after a visit to see how things were going). Subscale scores are calculated as means of the items within each subscale. Patient Activation
	Costs: NR
	Biomedical: NR
Simon & Sawicki	Psychological and wellbeing: Patients' willingness to attend SMA
2015	Behavioural: SMA attendance
(Hypertension)	Costs: NR
	Other: NR

	Biomedical: Attained a goal of A1C of 7%, proportion of participants who attained the ADA guideline recommendations for blood pressure and fasting lipid levels, 10-year risk of cardiac events,							
Taveira (2011)	Psychological and wellbeing : Perceived Competence Diabetes Scale, Patient Health Questionnaire-9 Depression Scale							
(Diabetes and depression)	Behavioural: Summary of Diabetes Self-Care Activities, number of patients who used tobacco (average daily number of cigarettes), medication changes (dose increase or initiation of any antihypertensive/antihyperglycemic agent/antihyperlipidemic/antidepressants), healthcare utilisation (primary care provider visits, emergency department visits, hospital admission rates),							
	Costs: NR							
	Other: deaths							
	Biomedical : Time to failure for guideline recommended goals of HbA1c and BP, Maintenance of goals for LDL, change in prescribed medications							
Tavoira 2014	Psychological and wellbeing: NR							
(Diabetes and CVD	Behavioural: hospital admissions and ED visits							
risk)	Costs: NR							
	Other: NR							
	Biomedical : HbA1C (not measured for participants with pre-diabetes, achieved target A1C%), weight (> 5% weight loss), lipid levels (total cholesterol, HDL, LDL, triglyerides, SBP, DBP, BMI							
Voughon 2017	Psychological and wellbeing: NR							
(Dishotos)	Behavioural: NR							
(Diabeles)	Costs: NR							
	Other : 8 standards of care per ADA and USPTF: weight loss, lipid levels, retinal screening, foot exam (i.e., assessment of foot pulses, sensation, skin exam), urine microalbumin, cancer screening (breast, cervical, colorectal)							
	Biomedical: HbA1C (%), cholesterol (mean mg/dl)							
	Psychological and wellbeing : health status (general health, physical function, physical role limitation, bed disability days, restricted activity day, depression (Center for Epidemiological Studies Depression Scale), satisfaction (medical care satisfaction, diabetes care satisfaction)							
Wagner 2001 (Diabetes)	Behavioural : healthcare utilisation (primary care visits, ER visits, speciality visits, hospital admissions)							
	Cost: NR							
	Other : receipt of recommended preventative manoeuvres (prevention procedures, medication review, retinal eye exam, foot examination, microalbumin test), use and helpfulness of patient education (written material, classes, face-to-face counselling)							

	Biomedical: Coronary Event Risk score, HbA1c %, systolic BP, LDL,
Wu 2018	Psychological and wellbeing : health-related quality-of-life (veteran version of Medical Outcomes Study survey (SF-36v)
(Diabetes and CVD)	Behavioural: NR
	Costs : healthcare costs (provider time in the group medical visits, medications, hospitalisations, ED visits, lab tests, procedures, referrals, outpatient clinic visits)
	Biomedical : HbA1c, hypoglycemic events, diabetes medication use, Weight, SBP, DBP, total cholesterol, LDL, HDL, waist circumference, triglycerides.
Yancy 2020 (Diabetes and	Psychological and wellbeing : diabetes related emotional distress (Problem Areas in Diabetes-PAID)
overweight)	Behavioural: Dietary adherence, physical activity, medication nonadherence
	Cost: Cost-effectiveness
*Como trial	

*Same trial

S5 – Quality assessment of included studies with sensitivity analyses

Table S5a: Quality assessments conducted for each included trial

				<u>Domain</u>			
	Select	tion bias	Performance bias	Detection bias	Attrition bias	Reporting bias	Other bias
<u>Study</u> Baqir (2016) Berry (2016) Clancy (2003) Clancy (2007)	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other sources of bias
Baqir (2016)	Low	Low	High	Low	Low	Unclear	Low
Berry (2016)	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Clancy (2003)	Low	Low	High	Low	Low	Unclear	Low
Clancy (2007)	Low	Low	High	Unclear	Low	Unclear	Low
Cohen (2011)	Unclear	Unclear	High	Unclear	Unclear	High	Low
Cole (2013)	Low	Low	High	Unclear	Low	Unclear	Low
Drake (2018)	Low	Unclear	High	Unclear	High	Low	High
Edelman (2010)	Unclear	Unclear	High	Low	Low	Low	Low
Ee (2020)	Low	Low	High	Low	Low	Low	Low
Gao (2015)	Unclear	Unclear	Unclear	Low	High	Unclear	High
Gardiner (2019)	Low	Low	High	Low	Low	Low	Low
Liu (2012)	Low	Unclear	High	Low	Unclear	Low	Low
Naik (2011)	Unclear	Low	High	Unclear	Unclear	Low	Low

Schillinger (2008)	Unclear	Unclear	High	Unclear	Low	Unclear	Low
Scott (2004)	Low	Unclear	High	Unclear	Low	Unclear	High
Simon (2015)	Unclear						
Taveria (2011)	Low	Unclear	High	Unclear	Low	Unclear	Low
Taveira (2014)	Unclear	Unclear	High	Unclear	High	Low	Low
Vaughan (2017)	Unclear	Unclear	Unclear	Unclear	Low	Unclear	Low
Vaughan (2020)	Low	Unclear	High	Unclear	Unclear	Low	Low
Wagner (2001)	Unclear	Unclear	High	Unclear	Unclear	Unclear	Unclear
Wu (2018)	Low	Low	High	Low	High	High	Low
Yancy (2020)	Low	Low	High	Low	High	Low	High

Figure S5: Summary of each of risk bias



Sensitivity Analyses according to Risk of Bias Criteria

Table S5a: Comparison between mean effect sizes for HbA1c (%) according to risk of bias across domains

Domain	Post-intervention changes in HbA1c (%) (k=8)									
	Low risk		<u>Higł</u>	<u>n/Unclear</u> <u>risk</u>	<u>Confidence</u> Intervals	Sig				
	<u>n</u>	<u>d</u>	<u>n</u>	<u>d</u>						
Selection bias										
Random sequence generation	6	-0.074	3	-0.147	-0.74, -0.59	0.798				
Allocation concealment	4	0.140	5	-0.263	-0.93, 0.14	0.126				
Performance bias										
Blinding of participants and personnel	N/A – all high/unclear									
Detection bias										
Blinding of outcome assessment	2	0.088	7	-0.158	-1.09, 0.49	0.404				
Attrition bias										
Incomplete outcome data	5	-0.036	4	-0.169	-0.77, 0.49	0.620				
Reporting bias										
Selective reporting	3	-0.027	6	-0.136	-0.83, 0.58	0.691				

Domain	Post-intervention changes in diastolic blood pressure (k=8)								
	Low risk		<u>High/Unclear</u> risk		<u>Confidence</u> Intervals	<u>Sig</u>			
	<u>n</u>	<u>d</u>	<u>n</u>	<u>d</u>					
Selection bias									
Random sequence generation	3	-0.201	5	-0.115	-0.31, 0.48	0.617			
Allocation concealment	2	-0.052	6	-0.126	-0.63, 0.49	0.771			
Performance bias									
Blinding of participants and personnel	N/A – all high/unclear								
Detection bias									
Blinding of outcome assessment	2	-0.080	6	-0.210	-0.37, 0.11	0.241			
Attrition bias									
Incomplete outcome data	4	-0.189	4	-0.109	-0.21, 0.37	0.528			
Reporting bias									
Selective reporting	3	-0.089	5	-0.127	-0.41, 0.32	0.766			

Table S5b: Comparison between mean effect sizes for diastolic blood pressure according to risk of bias across domains

Domain	Post-intervention changes in total cholesterol (k=3)						
	Lo	<u>w risk</u>	<u>High/Unclear</u> <u>risk</u>		Confidence Intervals	<u>Sig</u>	
	<u>n</u>	<u>d</u>	<u>n</u>	<u>d</u>			
Selection bias							
Random sequence generation	2	0.014	1	0.021	-4.02, 4.04	0.985	
Allocation concealment	1	-0.422	2	0.032	-5.86, 6.77	0.529	
Performance bias							
Blinding of participants and personnel	N/A – all high/unclear						
Detection bias							
Blinding of outcome assessment	1	-0.422	2	0.032	-5.86, 6.77	0.529	
Attrition bias							
Incomplete outcome data	1	-0.422	2	0.032	-5.86, 6.77	0.529	
Reporting bias							
Selective reporting	2	0.014	1	0.021	-4.02, 4.04	0.985	

 Table S5c: Comparison between mean effect sizes for total cholesterol according to risk of bias across domains

 Domain
 Post-intervention changes in total cholesterol (k=3)

Domain	Post-intervention changes in high-density lipoprotein									
	<u>cholesterol (k=3)</u>									
	Lo	<u>w risk</u>	High/Unclear		<u>Confidence</u>	Sig				
		d	n	<u>115k</u>	Intervals					
Selection hias	<u> </u>	<u>u</u>	<u> </u>	<u>u</u>						
Random sequence generation	1	-0.050	2	0.504	-3.33, 4.44	0.321				
Allocation concealment	1	-0.050	2	0.504	-3.33, 4.44	0.321				
Performance bias										
Blinding of participants and personnel	N/A – all high/unclear									
Detection bias										
Blinding of outcome				N/A – all I	nigh/unclear					
Attrition bias										
Incomplete outcome data	2	0.170	1	0.550	-4.59, 5.35	0.509				
Reporting bias										
Selective reporting	N/A – all high/unclear									
n=frequencies, k=number of tests of	relatio	onships, <i>d</i>	=mea	n effect size	•					

Table S5d: Comparison between mean effect sizes for high-density lipoprotein cholesterol according to risk of bias across domains

p*< 0.05; *p*< 0.01; ****p*< 0.001.

<u>Domain</u>	Post-intervention changes in low-density lipoprotein cholesterol (k=5)									
	Low risk		High/Unclear risk		<u>Confidence</u> Intervals	<u>Sig</u>				
	<u>n</u>	<u>d</u>	<u>n</u>	<u>d</u>						
Selection bias										
Random sequence generation	2	0.042	3	-0.061	-1.03, 0.88	0.812				
Allocation concealment	2	0.042	3	-0.061	-1.03, 0.88	0.812				
Performance bias										
Blinding of participants and personnel				N/A – all ł	nigh/unclear					
Detection bias										
Blinding of outcome assessment	1	0.140	4	-0.097	-1.18, 0.71	0.482				
Attrition bias										
Incomplete outcome data	2	0.067	3	-0.072	-1.14, 0.86	0.685				
Reporting bias										
Selective reporting	1	-0.020	4	-0.034	-1.18, 1.15	0.971				

Table S5e: Comparison between mean effect sizes for low-density lipoprotein cholesterol according to risk of bias across domains

Table S5f: Comparison between mean effect sizes for triglycerides according to risk of bias across domains

Domain	Post-intervention changes in triglycerides (k=4)								
	Low risk		<u>Hig</u> ł	n/Unclear risk	Confidence Intervals	<u>Sig</u>			
	<u>n</u>	<u>d</u>	<u>n</u>	<u>d</u>	-				
Selection bias									
Random sequence generation	2	-0.210	1	-1.111	-5.27, 3.47	0.232			
Allocation concealment	1	0.118	2	-0.732	-10.96, 9.26	0.479			
Performance bias									
Blinding of participants and personnel	N/A – all high/unclear								
Detection bias									
Blinding of outcome assessment	1	0.118	2	-0.732	-10.96, 9.26	0.479			
Attrition bias									
Incomplete outcome data	1	0.118	2	-0.732	-10.96, 9.26	0.479			
Reporting bias									
Selective reporting	2	-0.210	1	-1.111	-5.27, 3.47	0.232			

Table S5g: Comparison between mean effect sizes for BMI according to risk of bias across domains

Domain	Post-intervention changes in BMI (k=5)								
-	Low risk		<u>High/Unclear</u> risk		<u>Confidence</u> Intervals	<u>Sig</u>			
	<u>n</u>	d	<u>n</u>	<u>d</u>					
Selection bias									
Random sequence generation	2	0.278	3	0.039	-090, 1.09	0.789			
Allocation concealment	1	0.955	4	0.007	-2.84, 1.01	0.226			
Performance bias									
Blinding of participants and personnel	N/A – all high/unclear								
Detection bias									
Blinding of outcome assessment	2	0.361	3	-0.095	-1.32, 0.69	0.386			
Attrition bias									
Incomplete outcome data	3	0.101	2	0.000	-1.18, 0.97	0.771			
Reporting bias									
Selective reporting	2	0.278	3	0.039	-0.90, 1.09	0.789			

Table S5h: Comparison between mean effect sizes for self-efficacy according to risk of bias across domains

Domain	Post-intervention changes in self-efficacy (k=4)								
-	Lo	<u>w risk</u>	<u>Hig</u> l	h/Unclear risk	Confidence Intervals	<u>Sig</u>			
-	<u>n</u>	<u>d</u>	<u>n</u>	<u>d</u>					
Selection bias									
Random sequence generation	1	-0.282	3	0.373	-0.11, 1.42	0.066			
Allocation concealment	1	-0.282	3	0.373	-0.11, 1.42	0.066			
Performance bias									
Blinding of participants and personnel				N/A – all h	igh/unclear				
Detection bias									
Blinding of outcome assessment	2	0.069	3	0.336	-1.27, 1.78	0.547			
Attrition bias									
Incomplete outcome data	2	0.033	2	0.380	-0.99, 1.65	0.396			
Reporting bias									
Selective reporting	1	-0.282	3	0.373	-0.11, 1.42	0.066			

Table S5i: Comparison between mean effect sizes for depression according to risk of bias across domains

Domain	Post-intervention changes in depression (k=4)								
	Lo	<u>w risk</u>	<u>Hig</u> l	n/Unclear risk	<u>Confidence</u> Intervals	Sig			
	<u>n</u>	<u>d</u>	<u>n</u>	<u>d</u>					
Selection bias									
Random sequence generation	2	-0.326	2	-0.136	-1.04, 1.35	0.628			
Allocation concealment	2	-0.326	2	-0.136	-1.04, 1.35	0.628			
Performance bias									
Blinding of participants and personnel				N/A – all h	igh/unclear				
Detection bias									
Blinding of outcome assessment	3	-0.265	1	0.006	-1.34, 0.68	0.103			
Attrition bias									
Incomplete outcome data	2	-0.326	2	-0.136	-1.04, 1.35	0.628			
Reporting bias									
Selective reporting	2	-0.326	2	-0.136	-1.04, 1.35	0.628			

Table S5	i: Com	parison	between	mean	effect	sizes	for hos	spital	admissions	s according	a to i	risk o	f bias	across	domains
10010 00		paneon	00000000	mean	011000		101 110	opriori	aannoonon		,				aomanio

Domain	Post-intervention changes in hospital admissions (k=3)								
	Lo	<u>w risk</u>	<u>Hig</u>	<u>h/Unclear</u> <u>risk</u>	<u>Confidence</u> Intervals	<u>Sig</u>			
	<u>n</u>	<u>d</u>	<u>n</u>	<u>d</u>					
Selection bias									
Random sequence generation Allocation concealment	1	-0.277	2	0.173 N/A – all h	-1.95, 2.85 nigh/unclear	0.253			
Performance bias									
Blinding of participants and personnel				N/A – all h	nigh/unclear				
Detection bias									
Blinding of outcome assessment				N/A – all ł	nigh/unclear				
Attrition bias									
Incomplete outcome data	1	-0.277	2	0.173	-1.95, 2.85	0.253			
Reporting bias									
Selective reporting	1	0.294	2	-0.204	-3.51, 2.51	0.283			

<u>Domain</u>	Post-intervention changes in emergency department use (<i>k</i> =4)									
	Lo	<u>w risk</u>	Hig	<u>h/Unclear</u> <u>risk</u>	<u>Confidence</u> Intervals	<u>Sig</u>				
	<u>n</u>	<u>d</u>	<u>n</u>	d						
Selection bias										
Random sequence generation Allocation concealment	1	-0.310	3	0.048 N/A – all ł	-0.23, 0.94 nigh/unclear	0.118				
Performance bias										
Blinding of participants and personnel				N/A – all ł	nigh/unclear					
Detection bias										
Blinding of outcome assessment				N/A – all ł	nigh/unclear					
Attrition bias										
Incomplete outcome data	1	-0.310	3	0.048	-0.23, 0.94	0.118				
Reporting bias										
Selective reporting	1	0.000	3	-0.109	-1.40, 1.18	0.756				

Table S5k: Comparison between mean effect sizes for emergency department use according to risk of bias across domains

<u>Domain</u>	Pos	<u>st-interv</u>	<u>entio</u>	<u>n changes</u>	in primary care	visits (k=3)
	Lo	w risk	<u>Hig</u>	<u>h/Unclear</u> <u>risk</u>	<u>Confidence</u> Intervals	<u>Sig</u>
	<u>n</u>	<u>d</u>	<u>n</u>	<u>d</u>		
Selection bias						
Random sequence generation	2	- 0.035	1	0.074	-1.52, 1.74	0.552
Allocation concealment				N/A – all h	igh/unclear	
Performance bias						
Blinding of participants and personnel				N/A – all h	igh/unclear	
Detection bias						
Blinding of outcome assessment				N/A – all h	igh/unclear	
Attrition bias						
Incomplete outcome data	2	- 0.035	1	0.074	-1.52, 1.74	0.552
Reporting bias						
Selective reporting				N/A – all h	igh/unclear	

Table S5I: Comparison between mean effect sizes for primary care visits according to risk of bias across domains

S6 – Additional biomedical measures examined with forest plots

Total cholesterol

Five studies trials reported total cholesterol levels: four reported milligrams per deciliter (mg/dL) [25,37,39,46], and one reported millimoles per liter (mmol/L) [31]. Three of these trials which compared SMA to usual care were pooled together into a meta-analysis [31,37,39] where no statistically significant effect was found (d=0.022, 95%Cl = -0.12, 0.17, k=3, p=.767) (Figure S6a). Of the two studies which could not be included into the meta-analysis [25,46], only Edelman et al. (2010) reported significant group differences, whereby participants in the SMA group demonstrated lower total cholesterol levels at follow-up (153.9 mg/dL) than those in usual care (168.1 mg/dL) [46].

High density lipoprotein cholesterol

Five trials reported high-density lipoprotein (HDL) cholesterol [23,25,29,37,46]. Three of these studies were pooled into a meta-analysis [23,29,37]. A non-statistically significant small difference was found for HDL cholesterol between SMA and usual care at follow-up (d=0.312, 95%CI = -0.06, 0.68, k=3, p=0.100) (Figure S6b). Moderate levels of heterogeneity were found (I^2 =41.0%). Of the other trials which could not be included into the meta-analysis [25,46], Edelman et al. (2010) reported that participants in the SMA group demonstrated statistically significantly lower HDL at follow-up (39.3 mg/dL) than those in usual care (41.3 mg/dL) [46].

Low-density lipoprotein cholesterol

Nine trials reported low-density lipoprotein (LDL) cholesterol [23,25,26,29,37,40–42,46]. It was feasible to pool five of these studies [23,29,37,41,42]. SMAs showed no statistically significant difference to usual care on LDL cholesterol at follow-up (d=-0.027, 95%CI = -0.27, 0.22, k=5, p=0.830) (Figure S6c). Heterogeneity was moderate with an overall l^2 of 44.7%. Of the trials which could not be included into the meta-analysis, only Edelman et al. (2010) which looked at SMAs for patients with diabetes and hypertension, found that LDL was significantly lower for participants in the SMA group (M=84.1) than the control group (M=93.3) at follow-up [46].

Triglycerides

Triglycerides were measured in seven trials: mmol/L [31], mg/dL [23,25,26,29,37] and log mg/dL [46]. It was possible to meta-analyse three of these trials [23,31,37] which compared SMA to usual care. A small but non-statistically significant effect was found (*d*=-0.517, 95%*CI* = -1.22, 0.19, *k*=3, p=0.149) (Figure S6d). Of the other four trials which could not be included

in the meta-analysis, none reported any between-group differences for triglycerides at followup.

Weight

Weight (mean kg) was measured in five trials: [29,31,38,40,44]. A small but non-statistically significant effect was found (d=0.298, 95%*Cl* = -0.89, 1.49, k=2) (p=0.623) (Figure S6e). High levels of heterogeneity were observed (l^2 =79.3%). No significant group differences in weight were reported by the three other studies which could not be included into the meta-analysis [29,40,44].

BMI

Seven trials measured BMI kg/m² [29,31,32,34,37,38,50]. There was sufficient data to include four trials on diabetes [31,34,37,38] and a trial of patients with hypertension [50] in a metaanalysis. No statistically significant difference between SMAs and usual care was found for BMI (d=0.016, 95%CI = -0.19, 0.22, k=5) (p=0.876) (Figure S6f). The pooled effect remained similar when Ee et al. (2020) [31] as removed as an outlier in the sensitivity analysis due to wide 95% CIs, (d=-0.007, 95%CI = -0.15, 0.16, k=4)

None of the two trials which could not be included into the meta-analysis reported any significant differences between the SMA and control groups for BMI at follow-up [29,32].



Figure S6a: Forest plot for total cholesterol

Figure S6b: Forest plot for HDL



Figure S6c: Forest plot for LDL cholesterol



Figure S6d: Forest plot for triglycerides



Figure S6e: Forest plot for weight



Figure S6f: Forest plot for BMI



S7 – Additional psychological and well-being measures examined with forest plots

Depression

Of the six trials which reported on depression [22,31,32,39,43,50], it was possible to include four in a meta-analysis [22,31,39,50]. No statistically significance difference between SMAs and usual care for depression was found at follow-up (d=-0.173, 95%CI = -0.38, 0.03, k=4) (p=0.102) (Figure S7a). There was substantial heterogeneity at I^2 =69.3%.



Figure S7a: Forest plot for depression

Liu et al. (2012) and Taveira et al. (2011) did not find any differences in depression scores between the SMA and groups [32,43].

S8 – Additional behavioural outcomes examined with forest plots

Medication adherence

Four trials reported on medication adherence [40,46,50,52] but none reported significant differences between the SMA and usual care groups at follow-up.

Physical activity

Five SMA trials for metabolic LTCs [23,31,34,40,50] reported physical activity/exercise outcomes, with only Berry et al. (2016) reporting significant between group differences. Berry et al. (2016) measured patient participation (n= 80, sample majority non-Hispanic Black females) in five forms of physical activity during the past week: stretching and strengthening exercises, walking, swimming or aquatic exercises, bicycling, and other aerobic exercises. There were no significant differences found for any of these exercises, except patients in the SMA group engaged in more stretching and strengthening exercises (M=1.3, SD=1.2), compared to patients in the control group (M=0.4, SD=0.8) [23].

S9 – SMA delivery, dose and components

Mode of SMA delivery

In three trials [33,41,52] the intervention was delivered by a single healthcare professional. In the majority of trials, SMAs were delivered by multidisciplinary teams of interventionists; 15 trials included family physicians [19,23,24,30-34,39,44,46,50,51,53], two trials included specialist diabetes nurse [25,43], five trials included nurse practitioners [23,26-29,32,44,45], seven trials included nurses [19,20,39,40,42,46-50,53] and one trial included a non-specific prescribing clinician' [21,22]. Allied health professionals were involved in the intervention delivery; nine trials included pharmacists [19,20,39,41-43,46-49,52,53], pharmacist with diabetes specialism [40] five trials included dietitians [19,20,29,40,43–45], three trials included physical therapists [19.20.40.42], two involved community health workers [37,38,50], social workers[19,20,53] and or meditation teacher/non prescriber trained in mindfulness or yoga [21,22,31]. Other trials included nutritionists [29,42], healthcare assistants [53], diabetes health educators [31,34–36,44–49] a health coach [30] a registration clerk [53], patient representative group leader [32] and 'trained interventionist' [23]. It was not possible to tell what role each member of staff had in the delivery of the SMA, and whether it was the same of staff to deliver the SMAs each time. The individual consultation component of the intervention was conducted by a physician and/or nurse in twelve trials,[19,22-24,26,31,34,37–39,50,51] pharmacists in three trials [41–43] or was unspecified 'members of the team/clinician' in other studies [32,33,52] (see Table S9).

Provider characteristics other than profession or role were rarely reported. One trial of SMAs for patients with hypertension reported that the physician was female and self-employed [51]. Two trials for diabetic patients involving a majority Hispanic/Latino participants reported that the community health worker and or physician were bilingual, English-Spanish speaking [34,38].

Provider training was reported in several trials and included either 'on the job' training [26,52] and or attendance at a workshop led by those experienced in delivering SMAs. These workshops ranged in duration from 3 hours [27], to one day [32], to 3.5 days [50]. Length of workshop not reported in a fourth trial [33]. Some studies reported the that some providers had undergone training in group facilitation [46], chronic disease management [37,38] or goal setting [33]. One trial reported that clinicians had the opportunity to observe an SMA [25] or pilot the SMA before the study started [33]. Several trials involving patients with diabetes reported that the provider was a certified diabetes educator [40,42–44,46].

Four trials reported that the same interventionists attended all visits for a particular group [40,44,46,51]. One trial of diabetes SMAs reported that group assignments were maintained for all intervention sessions to facilitator peer interactions and relationships within groups [33]. The consistency in group composition in terms of patient and interventionists was not reported by most studies.

SMA frequency and dose

The size of each group session ranged from four [40] to 25 [32] patients per group, the most common group size reported was 6-9 patients per group (see Table S9). No studies reported how patients were allocated the SMA sessions (only how they were allocated treatment arm), therefore it is assumed that the groups were mixed in terms of gender, age, ethnicity. A trial of SMAs for older patients reported that family member or carers were encouraged to attend the SMAs sessions [19,29], though it is unclear whether these were excluded from the total number of participants reported or not.

The frequency and duration of the intervention ranged from a single SMA [52], to a series of 16 sessions over the study period [44,45]. Of the trials in which more than one SMA was held, most were conducted monthly [19,25,26,29,30,32,34,37,38], some were held weekly [22,43] others were held weekly to begin with then monthly [40,42]. One trial held SMAs bi-weekly [31] and one trial held SMAs tri-weekly [33]. Two trials held SMAs bi-monthly [46,51], one trial held SMAs tri-monthly [23]. Others trials reported greater variability in frequency; every 3-6 weeks [41], intensive sessions followed by tri monthly sessions [50] or SMAs every 3-6 months [39].

It is difficult to summarise the overall session duration (exposure) as some studies include the arrival and introductions as part of the session and others do not, similarly some studies include the 1:1 consultations as part of the group sessions and others do not. The duration of the sessions reported were typically between 90 [29,34,40,52] and 120 minutes [19,26,30,31,42,43,46,50] however they varied considerably between trials (See Table 3). The shortest duration reported was 30 minutes [41] though this excludes the time taken for the individual consultation at the end of the session. The longest SMA reported was 'half a day' [31] though these occurred less frequently (every 3-6 months). Four studies did not report the length of the SMA sessions [23–25,33,44,45,53].

SMA intervention components

Details of intervention components and mode of delivery reported by studies varied. See Table eS9. SMAs were described as 'group medical visits' [23,37,38], or 'group visits (cooperative

healthcare clinic)' [19–22,24–28,32,34–36,39,41,42,44,45,50,51] in thirteen trials, 'SMAs' in five trials [29–31,40,53] 'group clinics' [33,46] in two trials, 'chronic care clinic' [39] and 'group medical appointments' [43] and 'group consultations' [52] in one trial, respectively.

A key feature of all SMA interventions was the opportunity for each patient to have an individual 1:1 consultation with a clinician for one or a combination of the following exercises: [26,30]. medication/prescription physical assessment review/ adjustments [22,23,25,26,33,34,37,38,42-44,46,50]. goal setting [30,46]. counselling [39,42]. immunisations [24,26], discussion of issues [19,20,31,50,52] review health indicators or goals [29,32,33,40]. These 1:1 consultations occurred at every group session or at least one of the group sessions in a series of sessions (e.g. session 2 [30]).

In most trials (*n*=13) these individual assessments were conducted / offered to all participants during the group session [22,26,29,31,33,34,37–39,41–43,46,51]. In two trials this component was optional, or offered 'as needed' at the very end of the group session [32,50] or immediately after the group session had ended [19,20,24,25,52]. The option to have the individual assessments conducted privately away from the rest of the group members was specified in 3 trials [25,26,52]. Rather than having a 1:1 consultation immediately after the group session, in one trial telephone contact was made with selected patients on an as needed basis to follow-up lab values, self-care monitoring or medication changes [41].

Another feature common to fifteen trials was a facilitated group discussion, or group question and answer session [19,20,23,24,26,29,30,32–34,37–39,50–52]. 'Group education' component was described in thirteen trials [19,23,25,31–33,37,38,42,43,46,50] of which five involved presentations/ lectures from the healthcare professionals [19,24,41–43]. One study of SMAs for diabetes and cardiovascular disease risk included demonstration and coaching of self-care skills [41].

Individual goal setting or action planning was described in 12 trials: lifestyle goals [29,31,41,43,46–49], including dietary goals [40], weight goals [44] health related goals [30], self-management action plans [32–36,41] or therapeutic action plans [42].

Health data collection, including supervised self-assessments, was a component of six SMA interventions. In trials of diabetes SMAs, this included blood glucose self-assessment [46], the collection of 'lab and vitals' [37,38], or health self-assessments [30]. Patient-measured bone fracture risk calculations (FRAX) were collected in the SMA intervention for osteoporosis [52],

vital signs, mood state and pain levels were taken by patients at the start of an SMA for chronic pain and depression [22].

Written information provision in the form of handouts was provided in four trials outlining information about the condition [31,52] or nutritional advice [44]. In two trials patients were provided with meditation logbooks [31], or personal risk report cards [41].

Opportunity to socialise was specifically mentioned in eleven trials either by way of a warmup at the start of the SMA [19,25,26,29,32,34,46,50] or a during a meal towards the end [22,37,38]

			Section				SMA	compon	ents			
Trial	Characteristics of providers (roles within SMA)	Patients per group (n)	frequency (n) and each session duration (mins)	1:1 consultation during group	1:1 consultation after group	Socialisation	Facilitated group discussion/Q&A	Presentation/ education	Written information	Individual goal setting/ action planning	Tools for self- monitoring	self-health assessments/ data collection
Scott (2004)[19]	General practitioner/family physician, general nurse, pharmacist, occupational therapist, physiotherapist and dietitian. Receptionist handled scheduling	8-12 (+caregivers and spouses were invited to attend) 7.7 attended each CHCC group (mean)	Monthly for 24 months, 150 mins	V		V	V	√'		\checkmark	\checkmark	V
Gardiner (2019)[22]	Prescribing clinician (facilitator) non- prescriber trained in Mindfulness Based Stress Reduction (MBSR) or yoga (co-facilitator)	NR	9 'in-person' sessions, (weekly over 9 weeks), session duration: 150 mins, Electronic resource access only (over 12 weeks), 10th 'in person' session in week 21, session duration: 150 mins	\checkmark		\checkmark	\checkmark					\checkmark
Berry (2016)[23]	Adult health nurse practitioner, a physician, a postdoctoral	NR	5 sessions,	\checkmark				√p				

Table S9 – Description of SMA intervention composition, duration and components

	fellow (clinicians) trained interventionist (facilitator)		tri- monthly, over 15 months, duration: NR							
Clancy (2003)[25]	Hospital physician and specialist nurse (roles NS)	19-20	Monthly for 6 months duration: NR		\checkmark	\checkmark	\checkmark	√p		
Clancy (2007)[26]	Primary care internal medicine physicians, registered nurses (roles NS) Nutrition technician (screener) a dietitian or	14-17	Monthly for 1 year, 2 hours	√private		\checkmark	\checkmark			
Cole (2013)[29]	nutrition technician (session recorder) a certified diabetes educator registered dietitian (provider) and a behavioural specialist, registered nurse or registered dietitian trained in group dynamics (facilitator)	6-8 (+family members, friends, and other sources of social support)	Monthly over 3 months, 90 mins	\checkmark		\checkmark	\checkmark		\checkmark	
Drake (2018) [30]	Family medicine physician, health coach	7 or 12?	8 sessions, approx. monthly over 7 months, 120 mins	\checkmark			\checkmark		\checkmark	\checkmark

Ee (2020) [31]	GP, accredited diabetes educator, Meditation teacher	6-12	6 sessions, Bi- weekly, over 3 months, 120 mins	\checkmark				√ props	\checkmark	\checkmark	
Liu (2013)[32]	General practitioner/family physician, preventive doctor and general nurse practitioner (group facilitators- they alternated leading the 12 group self- management education sessions based on their areas of expertise). Patient rep leader to help coordinate implementation.	20-25	Monthly for 12 months Session duration: 150 mins		√selected patients only	V	\checkmark	\checkmark		V	
Naik (2011)[33]	Primary care physicians (role NS)	5-7	Four visits, every 3 weeks 70mins	\checkmark			\checkmark	√unclea r		\checkmark	
Schillinger (2008) [34]	language- concordant physician and health educator (roles NS)	6-10	Monthly for 9 months Session duration: 90mins	\checkmark		\checkmark	\checkmark			\checkmark	
Vaughan (2017) [37]	(clinician) Community Health workers integrated into leadership team (facilitator) CHW selected had 'personality characteristics of flexibility	25 participants at session (split into 3 smaller groups during session)	6 sessions, Monthly, Over 5 months, Session duration: 180mins	\checkmark		\checkmark	\checkmark	√'large group education'			

 \checkmark

Vaughan (2020)[38]	compassion, and determination' Bilingual physician (clinician) community health worker (group lead) CHW self- identified as Latino, fluent Spanish, CHW certification	NR	Monthly for 6 months Session duration: 3 hours	V		\checkmark	\checkmark	√'large group education'				V
Wagner (2001)[39]	Primary care practitioner, nurse and clinical pharmacist (roles NS)	6-10	Every 3-6 months, session duration: half- day	\checkmark			\checkmark					
Cohen (2011)[40]	Clinician pharmacist- nationally certified diabetes educator, dietitian, nurse and physical therapist (educator)	4-6	4 once-weekly 2-hour sessions and 5 monthly sessions of 90mins	√unclear			\checkmark		\checkmark	\checkmark		
Taveira (2014)[41]	Clinical pharmacist (role NS)	6-8	Once every 2-6 weeks until CV risk goal attainment reached. Patients that attained goals followed every 3 months (over 12 months) Session duration; 30 mins		V		\checkmark	\checkmark	V	\checkmark	\checkmark	
Wu (2018) [42]	Clinical pharmacist, nutritionist, nurse or physical	4-6	8 sessions, (Once weekly for over 4 weeks followed by 4 booster	\checkmark				\checkmark		\checkmark		

	therapist (roles NS)		sessions held once every 3 months for a total of 13 months.) Session duration: 120 mins							
Taveria (2011)[43]	Specialist nurse, pharmacist and dietitian (roles NS)	4-6	Four once weekly, session duration: 120 mins	\checkmark			√?	√L	\checkmark	
Yancy (2020)[44]	Physicians (2 general internists, 4 endocrinologists), Registered Dietitian, Registered Nurse, and/or Certified Diabetes Educator. (Roles NS)	8-15 (aim)	16 sessions, Bi- weekly over 16 weeks, every 8 weeks thereafter, Session duration:	\checkmark				\checkmark	\checkmark \checkmark	
Edelman (2010)[46]	General internist, a pharmacist and a nurse or certified diabetes educator	7-9 (6-8)	Every 2 months for seven visits over 12 months, 90-120mins		\checkmark	\checkmark	\checkmark	√E	\checkmark	\checkmark
Gao (2015) [50]	GP, nurse, community health worker	18-20	6 intensive sessions (over 3 months) followed by continuous sessions (over 6 months), 120 mins		√selected patients	\checkmark	\checkmark	\checkmark		

Simon and Sawicki (2015)[51]	Two female physicians. Both self-employed, work in solo practices, without institutional backing. (Roles NS)	12 invited. 5- 12 attendees (average 9.8)	6 sessions, bi monthly over 12 months, session duration: 75 mins	\checkmark		\checkmark		
Baqir (2016) [52]	Pharmacist external to practice (clinician)	13-25	One 90 mins		√selected patients	\checkmark	\checkmark	\checkmark

CHCC- Cooperative Health Care Clinic, P= presentation, L=lecture, E = education